Amedisys Inc (NASDAQ:AMED) – Research analysts at Oppenheimer Holdings lifted their FY2017 earnings per share estimates for shares of Amedisys in a note issued to investors on Wednesday. Oppenheimer Holdings analyst M. Wiederhorn now forecasts that the health services provider will post earnings per share of $2.23 for the year, up from their prior estimate of $2.22. Oppenheimer Holdings currently has a “Buy” rating and a $60.00 target price on the stock. Oppenheimer Holdings also issued estimates for Amedisys’ Q4 2017 earnings at $0.58 EPS, Q1 2018 earnings at $0.55 EPS, Q2 2018 earnings at $0.63 EPS and FY2018 earnings at $2.50 EPS.
AMED has been the subject of several other reports. Robert W. Baird raised their price objective on Amedisys from $50.00 to $60.00 and gave the company a “neutral” rating in a research note on Friday. Mizuho reaffirmed a “buy” rating and issued a $65.00 price objective (up from $55.00) on shares of Amedisys in a research note on Wednesday. BidaskClub lowered Amedisys from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Amedisys in a research note on Friday. Finally, Bank of America Corporation assumed coverage on Amedisys in a research note on Monday, August 21st. They issued a “neutral” rating and a $55.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $61.00.
WARNING: “Amedisys Inc Expected to Earn FY2017 Earnings of $2.23 Per Share (AMED)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/12/amedisys-inc-expected-to-earn-fy2017-earnings-of-2-23-per-share-amed.html.
Amedisys (NASDAQ AMED) opened at $56.25 on Friday. Amedisys has a one year low of $38.00 and a one year high of $65.91. The company has a market capitalization of $1,908.96, a P/E ratio of 26.91, a P/E/G ratio of 1.37 and a beta of 0.68. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.21 and a current ratio of 1.33.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The firm had revenue of $380.20 million during the quarter, compared to analysts’ expectations of $384.59 million. During the same quarter last year, the business posted $0.36 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis.
A number of hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its stake in Amedisys by 29.7% during the 3rd quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock worth $83,048,000 after buying an additional 339,825 shares during the last quarter. Virginia Retirement Systems ET AL purchased a new position in Amedisys during the 3rd quarter worth $1,802,000. Legal & General Group Plc grew its stake in Amedisys by 7.6% during the 3rd quarter. Legal & General Group Plc now owns 59,025 shares of the health services provider’s stock worth $3,303,000 after buying an additional 4,166 shares during the last quarter. FNY Managed Accounts LLC purchased a new position in Amedisys during the 3rd quarter worth $900,000. Finally, NorthCoast Asset Management LLC acquired a new stake in Amedisys during the 3rd quarter worth about $262,000. Hedge funds and other institutional investors own 96.36% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.